Omega-3 SPM Pro-Resolving.

E-series resolvins are made from EPA by sequential lipoxygenase steps. Without adequate EPA in membrane phospholipids the body has no substrate to form these mediators.

D-series resolvins, protectins and maresins are all enzymatic products of DHA. DHA intake sets the size of the pool these mediators are drawn from.

Fish oil delivers both EPA and DHA, the two fatty acids from which pro-resolving mediators are formed. Pairing keeps the precursor pool topped up while the finished mediators are supplied directly.

Krill oil carries EPA and DHA bound to phospholipids, which incorporate readily into cell membranes where the lipoxygenase enzymes act. That membrane pool is the working substrate for mediator formation.

Algal oil supplies DHA without a marine animal source, feeding the same D-series mediator route. Useful where a plant-sourced precursor is wanted alongside the mediators themselves.

Arachidonic acid and EPA compete for the same cyclooxygenase and lipoxygenase enzymes and for the same membrane positions. A high arachidonic acid load shifts enzyme output away from the omega-3 derived mediators.

GLA elongates to dihomo-gamma-linolenic acid and some of it carries on to arachidonic acid, which competes for the same enzymes. Co-dosing omega-3 with GLA is done to hold the balance of substrate entering those enzymes steady.

Highly unsaturated fatty acids peroxidise readily once the oil is exposed to air. Tocopherols are the standard chain-breaking antioxidant added to marine oil softgels to hold the fatty acids intact.

Rosemary diterpenes such as carnosic acid are a routine natural antioxidant system in marine oils. They work alongside tocopherols to slow peroxide formation during shelf life.

Astaxanthin sits across the lipid bilayer and quenches radicals in the same oil phase the mediators and their precursors occupy. It is commonly co-formulated with marine oils for that reason.

Marine omega-3 lipids lower platelet aggregation and nattokinase acts on fibrin. The two push normal clotting in the same direction, so the pairing warrants attention rather than assumed additive benefit.

Ginkgolides antagonise platelet activating factor while omega-3 lipids lower thromboxane-driven aggregation. The two effects on normal platelet function add together.

Garlic organosulfur compounds inhibit platelet aggregation through a separate route from omega-3 lipids. Stacking both nudges normal platelet behaviour further in one direction.

Linoleic acid and the omega-3 fatty acids compete for the same delta-6 desaturase and elongase steps, and their downstream products compete for the same lipoxygenase and cyclooxygenase enzymes. A diet heavy in linoleic acid shifts the mediator pool that those enzymes produce away from the omega-3 derived side. That competition is established enzymology and it is the reason the omega-6 to omega-3 ratio is discussed at all.

Long-chain fatty acids and their hydroxylated derivatives need bile salts to form the mixed micelles that carry them to the intestinal brush border. Where bile output is low, fat absorption is the limiting step regardless of what the capsule contains. Supplemental bile components are used on that basis; this is digestive physiology rather than a combination finding.

Pancreatic lipase with colipase cleaves dietary triglyceride into free fatty acids and monoglycerides, which is the form that is absorbed. A marine oil supplied as triglyceride depends on that step. A supplemental lipase supports the same hydrolysis in the lumen, though whether it changes absorption in someone with normal pancreatic function is not established.

Phospholipids emulsify oil into fine droplets, increasing the surface area available to lipase and reducing dependence on bile output. Phosphatidylcholine is the usual choice in marine oil formulations for that reason, and it also carries a small choline contribution. The chemistry is settled; the size of any absorption gain depends on the specific formulation.

Medium-chain triglycerides are hydrolysed quickly and absorbed with far less reliance on bile and micelle formation than long-chain fats, which is why they are used as a carrier oil for lipid-soluble actives. In a softgel they keep the oil phase fluid and help disperse it. They are a vehicle here, not a second pro-resolving compound.

Glutathione peroxidase 4 is a selenoenzyme that specifically reduces lipid hydroperoxides in membranes, and the hydroxylated polyunsaturated fatty acids in an SPM concentrate are exactly the kind of substrate that oxidises. Selenium status therefore bears on the fate of these lipids in the body. The enzymology is established; the pairing has not been trialled.

Ascorbate reduces the tocopheroxyl radical back to tocopherol, which is how the lipid-phase antioxidant in a marine oil keeps working. That recycling loop is standard antioxidant biochemistry and it applies to any highly unsaturated oil. It concerns the integrity of the oil and its lipids, not an added biological effect.

Vitamin D acts through a nuclear receptor that influences macrophage phenotype and immune cell differentiation, while pro-resolving mediators act on cell surface G-protein-coupled receptors on many of the same cells. Two different receptor families converging on macrophage behaviour is the rationale for combining them. Reviews of SPM biology describe that macrophage step; none of them tested this pair.

Curcuminoids influence the same cyclooxygenase and lipoxygenase enzymes that convert EPA and DHA into pro-resolving mediators, so the interaction is not purely additive. Suppressing an enzyme can reduce the production of a mediator that depends on it, which is a real consideration and rarely stated in blends that carry both. Curcumin also has its own effect on platelet function, worth noting alongside a marine oil.

Boswellic acids act on 5-lipoxygenase, the same enzyme that performs one of the oxygenation steps producing resolvins from EPA. Pairing an inhibitor of that enzyme with substrate for it cuts both ways, which is worth saying plainly rather than describing the combination as simply complementary. No study has measured the two together.

Gingerols reduce platelet aggregation in laboratory and human studies, and marine oils at higher intakes lengthen bleeding time. Those effects add, which is the reason to flag the pairing rather than to present it as a benefit. Anyone on anticoagulant or antiplatelet medication should have this combination reviewed by a clinician.

Bromelain influences platelet aggregation and fibrinolytic activity, and it is commonly formulated alongside marine oils in products aimed at recovery. Two agents acting on the same clotting-related processes are additive by default. Flag it, do not sell it.

Willow bark supplies salicin, which is metabolised to salicylate and acts on the cyclooxygenase pathway that platelets depend on. Taken with a marine oil at higher intake, the effects on platelet function add. Note that the specific aspirin-triggered pathway that generates 15-epi-lipoxins depends on acetylation of COX-2, which is a property of acetylsalicylic acid and not of salicin, so that particular mechanism should not be claimed for willow bark.